Category - Developments

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the company reported additional positive data for its voclosporin drug candidate in patients with active lupus nephritis...

Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current...

Profound Medical (TSX-V:PRN) has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO system. TULSA-PRO, which received CE Mark approval in April 2016...

Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA).  The company recently completed its pivotal Phase 3 clinical trials...

Cellectar Biosciences (NASDAQ:CLRB) reported positive data from the second cohort of patients enrolled in its orphan-drug designated Phase 1 study of CLR 131 in patients with relapsed or refractory multiple myeloma...

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin achieved its primary endpoint of complete remission (CR) at 24 weeks in a Phase 2b trial. In addition, when both doses of voclosporin were added to the current...

Galectin Therapeutics (NASDAQ:GALT) has completed enrollment one month early in its Phase 2b trial (NASH-CX) with 162 subjects with nonalcoholic steatohepatitis (NASH). The Phase 2b study is testing the company’s GR-MD...

USA Today has carried a profile of Sarah Wilson, wife and mother of four, who became addicted to opioid pain medications after she suffered severe injuries from being hit by an intoxicated driver about eight-years-ago...

Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice.  Mr. Stern will also continue to spend a portion of...

The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer In a statement, Paul Gunn...